Abstracts tagged "T Cell"

Abstract Number: 0004 • ACR Convergence 2024
Beyond Antibodies and CAR-T: Topologically Engineered, Superdimeric Antibody NK Engagers and T Cell Engagers for B Cell Depletion Demonstrating Cooperative Binding to Target and Effector Cells
Daniel Capon, Larisa Troitskaya, Marina Fomin, Brendon Frank, Ursula Edman, Benjamin Capon, Brian Law, Steven Chapin, Gavin Lewis, Malcolm Gefter, Juha Punnonen and Nelson Chan, Hinge Bio, Inc., Burlingame, CA
Background/Purpose: The dramatic demonstration of CD19 CAR-T efficacy in systemic lupus erythematosus (SLE), idiopathic inflammatory myositis, and systemic sclerosis by Georg Schett and colleagues (F.…
Abstract Number: 0512 • ACR Convergence 2024
Co-stimulatory Blockade Causes Targeted Quantitative and Clonotypic Contractions in Extrafollicular B-cell Subsets in Seropositive RA Patients
Jasmine Shwetar¹, William Rigby², Sladjana Skopelia-Gardner³, Abhimanyu Armarnani¹, Kelly Ruggles¹ and Gregg Silverman¹, ¹NYU Grossman School of Medicine, New York, NY, ²Dartmouth-Hitchcock, Norwich, VT, ³Dartmouth Hitchcock Medical Center, Hanover, NH
Background/Purpose: Of all approved biologic therapies, other than anti-CD20 depletion only CTLA4-Ig/abatacept treatment reduces levels of pathologic autoantibodies. Herein, our primary goal has been to…
Abstract Number: 1381 • ACR Convergence 2024
Elimination of CD45RChigh T and B Cells by anti-CD45RC mAb Lead to Efficient Control of Experimental Rheumatoid Arthritis
Cécile Bergua¹, Marine Besnard¹, Ghenima Ahmil², Laure-Helene Ouisse², Nadège Vimond¹, Apolline Salama², Bérangère Evrard², Elise Brisebard³, Alexis Collette¹, Fréderic Blanchard⁴, Thibault Larcher³, Ronald Van Brempt¹, Benoit Le Goff⁵, Ignacio Anegon² and Carole Guillonneau¹, ¹AbolerIS Pharma, Nantes, France, Nantes, France, ²Nantes Université, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, CNRS, Nantes, France, Nantes, France, ³APEX-UMR703 PAnTher INRA/ONIRIS, France, Nantes, France, ⁴INSERM UMR1229, Nantes, France, Nantes, France, ⁵CHU Nantes, France, Nantes, France
Background/Purpose: CD45RC is an isoform of CD45, a transmembrane tyrosine phosphatase, essential regulator of T and B cells antigen receptor signaling, expressed by most blood…
Abstract Number: 1790 • ACR Convergence 2024
Response Gene to Complement-32 Expression Is Upregulated in Lupus T Cells and Promotes Th17 Differentiation
Violeta Rus¹, Vinh Nguyen¹, Alexandru Tatomir¹, Cornelia Cudrici² and Horea Rus¹, ¹University of Maryland at Baltimore, Baltimore, MD, ²National Institute of Health, Bethesda, MD
Background/Purpose: RGC (Response Gene to Complement)-32 is a cell cycle regulator expressed in normal tissues, tumors and a variety of cell lines. RGC-32 plays a…
Abstract Number: 1852 • ACR Convergence 2024
Uncovering a MAIT-Treg Axis in Skin UV Response: Implications for Photosensitive Reactions in Cutaneous Lupus Erythematosus
Grace Crossland¹, Lindsay Mendyka², Kaitlyn Dowling³, Michael Constantinides⁴ and Sladjana Skopelja-Gardner¹, ¹Dartmouth Geisel School of Medicine, Lebanon, NH, ²Dartmouth Hitchcock Memorial Hospital, Lyme, NH, ³Dartmouth College, Lebanon, NH, ⁴Scripps Research Institute, San Diego, CA
Background/Purpose: Approximately 80% of cutaneous lupus erythematosus (CLE) patients experience sensitivity to ultraviolet (UV) sunlight rays, which leads to disfiguring skin lesions or systemic disease…
Abstract Number: 2004 • ACR Convergence 2024
Rheumatic Complications Post-CAR-T Cell Therapy. Experience of a Single Center
Jose Alfredo Gomez-Puerta¹, Ana Monegal¹, Andrés Ponce², Pilar Peris³, Nuria Martínez⁴, Valentin Ortiz-Maldonado⁴, Ana Triguero⁴, Carlos Fernández de larrea⁴, Julio Delgado⁴, Raimon Sanmartí Sala¹ and Manuel Juan⁵, ¹Rheumatology Department, Hospital Clinic of Barcelona, Barcelona, Spain, ²Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, ³Rheumatology Department, Hospital Clínic de Barcelona, Barcelona, Spain, ⁴Haematology Department, Hospital Clinic of Barcelona, Barcelona, Spain, ⁵Immunology Department, Hospital Clinic of Barcelona, Barcelona, Spain
Background/Purpose: CAR-T cell therapy is a promising treatment for a range of systemic autoimmune diseases such as systemic lupus erythematosus, systemic sclerosis, and antisynthetase syndrome,…
Abstract Number: 0008 • ACR Convergence 2024
Preclinical Development and Manufacturability of KYV-201, an Investigational Allogeneic Anti-CD19 Chimeric Antigen Receptor T Cell for the Treatment of Autoimmune Disease
Ashley Mahne¹, Ryan Rodriguez², Jessica Wang¹, Daniel Anaya¹, Joseph K. Cheng¹, Brandon Kwong¹, Jesus Banuelos³, Peter Starokadomskyy³, Soo Park³, Candice Gibson⁴, Shouvonik Sengupta¹, Simone Sandoval¹, Jazmin Bravo³, Jeanne Flandez¹, Shairaz Shah¹, Amanda Goodsell¹, Nicole Khoshnoodi¹, Jennifer Zeng¹, Santiago Foos-Russ¹, Mario Lorente¹, Jennifer Adrian¹, Timothy Klasson¹, Yong Zhang⁵, Jessica Seitzer⁶, Birgit Schultes⁵ and Tom Van Blarcom³, ¹Kyverna Therapeutics, Inc., Emeryville, CA, ²Kyverna Therapeutics, Inc., Emerville, CA, ³Kyverna Therapeutics, Inc., Emeryville, ⁴Kyverna Therapeutics, Inc., Emerybille, ⁵Intellia Therapeutics, Inc., Cambridge, MA, ⁶Intellia Therapeutics, Inc., Cambridge
Background/Purpose: Autologous anti-CD19 chimeric antigen receptor (CAR) T cells show early clinical evidence of safety and efficacy for treating several autoimmune diseases (Müller F. N Engl…
Abstract Number: 0776 • ACR Convergence 2024
Follicular Dendritic Cell PD-L1 Expression Promotes Autoreactive Germinal Center Formation
Elliot Akama-Garren¹, Yingying Zhang², Balthasar Heesters³, Padraic Fallon⁴ and Michael Carroll², ¹Harvard Medical School, Boston, MA, ²Boston Children's Hospital, Boston, MA, ³Utrecht University, Utrecht, Netherlands, ⁴Trinity College Dublin, Dublin, Ireland
Background/Purpose: Germinal center (GC) responses generate humoral immunity through coordinated interactions between B cells and T follicular helper (TFH) and T follicular regulatory (TFR) cells.…
Abstract Number: 1382 • ACR Convergence 2024
Synovial Expression Levels of PD-1, the Target of Rosnilimab, Correlate with Disease Activity and Persist Across Disease Stages and Lines of Therapy in Rheumatoid Arthritis
Yangsu Ren¹, Catherine Aversa¹, Myles Lewis², Cankut Cubuk³, Felice Rivellese⁴, Liliane Fossati-Jimack³, Pejman Soroosh¹, Amy Archer¹, Martin Dahl¹, Paul Lizzul¹, Cailin Sibley¹ and Costantino Pitzalis⁵, ¹AnaptysBio, San Diego, CA, ²Queen Mary University of London, London, United Kingdom, ³Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London and Barts NIHR BRC & NHS Trust, London, EC1M 6BQ, London, United Kingdom, ⁴Centre for Experimental Medicine & Rheumatology, Queen Mary University of London, London, United Kingdom, ⁵QMUL, Bromley Kent, United Kingdom
Background/Purpose: Despite multiple approved therapies in rheumatoid arthritis (RA), many patients do not achieve clinically meaningful responses, emphasizing the need for novel therapeutics with improved…
Abstract Number: 1801 • ACR Convergence 2024
Inhibitory Effects of Dapirolizumab Pegol, a Monovalent Anti-CD40L PEG-Conjugated Antigen-Binding Fragment Lacking a Functional Fc Domain, on In Vitro T Follicular Helper/B Cell Interactions and Cytokine Production in Systemic Lupus Erythematosus
Tania Rowley¹, Adnan R. Khan¹, Laura McLaughlin¹, Hannah Cherry¹, Farnaz Fallah-Arani¹, Yiannis Ioannou¹, Debasish Pyne² and Anthony Shock¹, ¹UCB Pharma, Slough, United Kingdom, ²Barts Health NHS Trust, London, United Kingdom
Background/Purpose: The pivotal role of CD40-CD40L interactions in systemic lupus erythematosus (SLE) pathogenesis stems from the orchestration of a range of immune and inflammatory responses…
Abstract Number: 1853 • ACR Convergence 2024
Mutated Nod2 Enhances Pathogenic Th17 Responses That Promote Experimental Blau Syndrome
Leah Huey¹, Emily Vance¹, Kofi Asare-Konadu² and Ruth Napier³, ¹Oregon Health & Science University, Portland, OR, ²Department of Molecular Microbiology and Immunology, Oregon Health & Science University, Portland, OR, ³Department of Molecular Microbiology and Immunology and Division of Arthritis and Rheumatic Disease, Oregon Health & Science University, VA Portland Health Care System, Portland, OR
Background/Purpose: Blau syndrome, a pediatric rheumatological disease characterized by uveitis, arthritis, and dermatitis, is caused by a single point mutation in the gene NOD2. Nod2…
Abstract Number: 2254 • ACR Convergence 2024
A Phase 1 Single Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of ZB004, a CTLA-4-Ig Fusion Protein Designed for Increased Binding Affinity and Extended Half-life, in Healthy Volunteers
Cory Sellwood¹, Minggeng Gao², Sheen Zhang², Mark Matijevic², Stephen Wax³, Mason Yamashita², Shan Yu², Sujata Arora² and Rachel Kirk², ¹New Zealand Clinical Research, Christchurch, New Zealand, ²Zenas BioPharma, Waltham, MA, ³Former Employee of Zenas Biopharma, Newton, MA
Background/Purpose: ZB004 is a bioengineered cytotoxic T-lymphocyte-associated antigen 4 ‑immunoglobulin (CTLA-4-Ig) fusion protein. Its mechanism of action is selective inhibition of T lymphocyte (T cell)…
Abstract Number: 0010 • ACR Convergence 2024
Precision Editing of Cyclophilin a to Engineer Cyclosporine- and Voclosporin- Resistant Human CAR-T Cells
Holly Wobma¹, Francesca Alvarez-Calderon², Jiayi Dong², Alexandre Albanese², Kayleigh Omdahl², Rene Bermea³, Gillian Selig⁴, Marlana Winschel², Elisa Rojas Palato², Katherine Michaelis¹, Xianliang Rui², Bruce Blazar⁵, Susan Prockop², Victor Tkachev³, Ulrike Gerdemann² and Leslie Kean², ¹Division of Immunology, Boston Children's Hospital, Boston, MA, ²Division of Hematology-Oncology, Boston Children's Hospital, Boston, MA, ³Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA, ⁴Harvard College, Boston, MA, ⁵Division of Pediatric Blood and Marrow Transplantation & Cellular Therapy, University of Minnesota, Minneapolis, MN
Background/Purpose: With exponential demand for chimeric antigen receptor (CAR) therapies for autoimmune disease, allogeneic options will be essential. Advantages include use of healthy donor cells,…
Abstract Number: 0781 • ACR Convergence 2024
An Expanded Cytotoxic CD8 T Cell Population Regulated by CD155-CD226 in SSc-ILD
Takanori Sasaki¹, Ye Cao², Kathryne Marks³, Richard Ainsworth⁴, Kim Taylor⁵, Nunzio Bottini⁴, Mehreen Elahee⁶, Mari Kamiya³, Edy Kim⁶, Francesco Boin⁴ and Deepak Rao⁷, ¹Brigham and Women's Hospital and Harvard Medical School, Brookline, MA, ²Brigham and Women's Hospital and Harvard Medical School, Boston, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Cedars-Sinai Medical Center, Los Angeles, CA, ⁵University of California, San Francisco, CA, ⁶Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁷Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Interstitial lung disease (ILD) is a major cause of morbidity and mortality in systemic sclerosis (SSc). We aimed to identify circulating immune cells associated…
Abstract Number: 1415 • ACR Convergence 2024
Metformin Improves Salivary Gland Infiltration and Objective Measures of Dry Eyes in Sjögren’s Disease: A Retrospective Observational Study
Astrid Rasmussen¹, Alan Baer², Thomas Grader-Beck³, Margaret Beach⁴, Blake M. Warner⁵, Christopher Lessard¹, A. Darise Farris¹ and Robert Hal Scofield¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Johns Hopkins, Baltimore, MD, ⁴NIH/NIDCR, Arlington, VA, ⁵National Institutes of Health, Bethesda, MD
Background/Purpose: Metformin (Met) is a widely used, first-line antidiabetic drug with AMPK-dependent anti-inflammatory and immunomodulatory effects. In in vitro studies and human trials in SLE…

« Previous Page
1
…
4
5
6
7
8
…
26
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].